High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients

British Journal of Haematology

Volumn 144, Issue 4, 2009, Pages 524-530

  Van 't Veer, Mars B ^a   De Jong, Daphne ^b   MacKenzie, Marius ^c   Kluin Nelemans, Hanneke C ^d   Van Oers, Marinus H J ^e   Zijlstra, Jose ^f   Hagenbeek, Anton ^e   Van Putten, Wim L J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adriamycin; Ara C; Carmustine; Etoposide; High dose Ara C; Mantle cell lymphoma; Melphalan; Oncovin; Prednisolone; R cyclophosphamide

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; PREDNISOLONE; RITUXIMAB; VINCRISTINE SULFATE;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE MARKER; DOSE RESPONSE; GASTROINTESTINAL DISEASE; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PYREXIA IDIOPATHICA; SINUSITIS; STEM CELL TRANSPLANTATION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; PREDNISONE; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 58549085393     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07498.x     Document Type: Article

References (28)

1. Andersen, N.S., Pedersen, L., Elonen, E., Johnson, A., Kolstad, A., Franssila, K., Langholm, R., Ralfkiaer, E., Akerman, M., Eriksson, M., Kuittinen, O. Geisler, C.H. (2003) Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant. European Journal of Haematology, 71, 73 80.
2. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. Diehl, V. (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579 586.
3. Determann, O., Hoster, E., Ott, G., Wolfram, B.H., Loddenkemper, C., Leo, H.M., Barth, T.E., Unterhalt, M., Hiddemann, W., Dreyling, M. Klapper, W. (2008) Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood, 111, 2385 2387.
4. Dreger, P., Rieger, M., Seyfarth, B., Hensel, M., Kneba, M., Ho, A.D., Schmitz, N. Pott, C. (2007) Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome. Haematologica, 92, 42 49.
5. Dreyling, M., Lenz, G., Hoster, E., van Hoof, A., Gisselbrecht, C., Schmits, R., Metzner, B., Truemper, L., Reiser, M., Steinhauer, H., Boiron, J.M., Boogaerts, M.A., Aldaoud, A., Silingardi, V., Kluin-Nelemans, H.C., Hasford, J., Parwaresch, R., Unterhalt, M. Hiddemann, W. (2005) Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood, 105, 2677 2684.
6. Ek, S., Bjorck, E., Porwit-MacDonald, A., Nordenskjold, M. Borrebaeck, C.A. (2004) Increased expression of Ki-67 in mantle cell lymphoma is associated with de-regulation of several cell cycle regulatory components, as identified by global gene expression analysis. Haematologica, 89, 686 695.
7. Evens, A.M., Winter, J.N., Hou, N., Nelson, B.P., Rademaker, A., Patton, D., Singhal, S., Frankfurt, O., Tallman, M.S., Rosen, S.T., Mehta, J. Gordon, L.I. (2008) A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma. British Journal of Haematology, 140, 385 393.
8. Foran, J.M., Cunningham, D., Coiffier, B., Solal-Celigny, P., Reyes, F., Ghielmini, M., Johnson, P.W., Gisselbrecht, C., Bradburn, M., Matthews, J. Lister, T.A. (2000) Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Annals of Oncology, 11 (Suppl. 1 117 121.
9. Geisler, C.H., Kolstad, A., Laurell, A., Andersen, N.S., Pedersen, L.B., Jerkeman, M., Eriksson, M., Nordstrom, M., Kimby, E., Boesen, A.M., Kuittinen, O., Lauritzsen, G.F., Nilsson-Ehle, H., Ralfkiaer, E., Akerman, M., Ehinger, M., Sundstrom, C., Langholm, R., Delabie, J., Karjalainen-Lindsberg, M.L., Brown, P. Elonen, E. (2008) Long-term progression-free survival of mantle cell lymphoma following intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a non-randomized phase-II multicenter study by the Nordic Lymphoma Group. Blood, 112, 2687 2693.
10. Ghielmini, M., Schmitz, S.F., Cogliatti, S., Bertoni, F., Waltzer, U., Fey, M.F., Betticher, D.C., Schefer, H., Pichert, G., Stahel, R., Ketterer, N., Bargetzi, M. Cerny, T. (2005) Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). Journal of Clinical Oncology, 23, 705 711.
11. Gianni, A.M., Magni, M., Martelli, M., Di Nicola, M., Carlo-Stella, C., Pilotti, S., Rambaldi, A., Cortelazzo, S., Patti, C., Parvis, G., Benedetti, F., Capria, S., Corradini, P., Tarella, C. Barbui, T. (2003) Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood, 102, 749 755.
12. Hiddemann, W., Unterhalt, M., Herrmann, R., Woltjen, H.H., Kreuser, E.D., Trumper, L., Reuss-Borst, M., Terhardt-Kasten, E., Busch, M., Neubauer, A., Kaiser, U., Hanrath, R.D., Middeke, H., Helm, G., Freund, M., Stein, H., Tiemann, M. Parwaresch, R. (1998) Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. Journal of Clinical Oncology, 16, 1922 1930.
13. Hoster, E., Dreyling, M., Klapper, W., Gisselbrecht, C., van Hoof, A., Kluin-Nelemans, H.C., Pfreundschuh, M., Reiser, M., Metzner, B., Einsele, H., Peter, N., Jung, W., Wormann, B., Ludwig, W.D., Duhrsen, U., Eimermacher, H., Wandt, H., Hasford, J., Hiddemann, W. Unterhalt, M. (2008) A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood, 111, 558 565.
14. Howard, O.M., Gribben, J.G., Neuberg, D.S., Grossbard, M., Poor, C., Janicek, M.J. Shipp, M.A. (2002) Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. Journal of Clinical Oncology, 20, 1288 1294.
15. Jaffe, E.S., Harris, N.L., Stein, H. Vardiman, J.W. (eds 2001) World Health Organisation Classification of Tumours, pp. 186 170. IARC Press, Lyon.
16. Khouri, I.F., Romaguera, J., Kantarjian, H., Palmer, J.L., Pugh, W.C., Korbling, M., Hagemeister, F., Samuels, B., Rodriguez, A., Giralt, S., Younes, A., Przepiorka, D., Claxton, D., Cabanillas, F. Champlin, R. (1998) Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. Journal of Clinical Oncology, 16, 3803 3809.
17. Kienle, D., Katzenberger, T., Ott, G., Saupe, D., Benner, A., Kohlhammer, H., Barth, T.F., Holler, S., Kalla, J., Rosenwald, A., Muller-Hermelink, H.K., Moller, P., Lichter, P., Dohner, H. Stilgenbauer, S. (2007) Quantitative gene expression deregulation in mantle-cell lymphoma: correlation with clinical and biologic factors. Journal of Clinical Oncology, 25, 2770 2777.
18. Lefrere, F., Delmer, A., Suzan, F., Levy, V., Belanger, C., Djabarri, M., Arnulf, B., Damaj, G., Maillard, N., Ribrag, V., Janvier, M., Sebban, C., Casasnovas, R.O., Bouabdallah, R., Dreyfus, F., Verkarre, V., Delabesse, E., Valensi, F., McIntyre, E., Brousse, N., Varet, B. Hermine, O. (2002) Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia, 16, 587 593.
19. Lefrere, F., Delmer, A., Levy, V., Delarue, R., Varet, B. Hermine, O. (2004) Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study. Haematologica, 89, 1275 1276.
20. Lenz, G., Dreyling, M., Hoster, E., Wormann, B., Duhrsen, U., Metzner, B., Eimermacher, H., Neubauer, A., Wandt, H., Steinhauer, H., Martin, S., Heidemann, E., Aldaoud, A., Parwaresch, R., Hasford, J., Unterhalt, M. Hiddemann, W. (2005) Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Journal of Clinical Oncology, 23, 1984 1992.
21. Mangel, J., Leitch, H.A., Connors, J.M., Buckstein, R., Imrie, K., Spaner, D., Crump, M., Pennell, N., Boudreau, A. Berinstein, N.L. (2004) Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. Annals of Oncology, 15, 283 290.
22. Martin, P., Chadburn, A., Christos, P., Furman, R., Ruan, J., Joyce, M.A., Fusco, E., Glynn, P., Elstrom, R., Niesvizky, R., Feldman, E.J., Shore, T.B., Schuster, M.W., Ely, S., Knowles, D.M., Chen-Kiang, S., Coleman, M. Leonard, J.P. (2008) Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Annals of Oncology, 19, 1327 1330.
23. Ritchie, D.S., Seymour, J.F., Grigg, A.P., Roberts, A.W., Hoyt, R., Thompson, S., Szer, J. Prince, H.M. (2007) The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Annals of Hematology, 86, 101 105.
24. Romaguera, J.E., Fayad, L., Rodriguez, M.A., Broglio, K.R., Hagemeister, F.B., Pro, B., McLaughlin, P., Younes, A., Samaniego, F., Goy, A., Sarris, A.H., Dang, N.H., Wang, M., Beasley, V., Medeiros, L.J., Katz, R.L., Gagneja, H., Samuels, B.I., Smith, T.L. Cabanillas, F.F. (2005) High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. Journal of Clinical Oncology, 23, 7013 7023.
25. Teodorovic, I., Pittaluga, S., Kluin-Nelemans, J.C., Meerwaldt, J.H., Hagenbeek, A., van Glabbeke, M., Somers, R., Bijnens, L., Noordijk, E.M. Peeters, C.D. (1995) Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. Journal of Clinical Oncology, 13, 2819 2826.
26. The International Non Hodgkin's Lymphoma Prognostic Factor Project. (1993) A predictive model for aggressive non-Hodgkin 's lymphoma. The international Non Hodgkin's Lymphoma Prognostic Factor Project. The New England Journal of Medicine, 329, 987 994.
27. Vandenberghe, E., Wolf-Peeters, C., Vaughan, H.G., Vaughan, H.B., Pittaluga, S., Anderson, L. Linch, D.C. (1997) The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group. British Journal of Haematology, 99, 842 847.
28. Velders, G.A., Kluin-Nelemans, J.C., De Boer, C.J., Hermans, J., Noordijk, E.M., Schuuring, E., Kramer, M.H., Van Deijk, W.A., Rahder, J.B., Kluin, P.M. Van Krieken, J.H. (1996) Mantle-cell lymphoma: a population-based clinical study. Journal of Clinical Oncology, 14, 1269 1274.